InMed Pharmaceuticals Inc. INM PHARMA
Company Overview
InMed Pharmaceuticals Inc. operates as a pharmaceutical drug development company in the United States. The company researches and develops cannabinoid-based pharmaceuticals products. Its product candidates include INM-901 for Alzheimer's disease, INM-089 for dry age-related macular degeneration, and INM-755, a cannabinol cream. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is based in Vancouver, Canada.
Why Investors Should Care
Revenue has grown at a 26.9% CAGR over the past five years.
Carries low leverage with a debt-to-equity ratio of 0.06.
Recent Developments
- Jun 2025 Revenue of $4.94M (+7.5% YoY); net profit $-8.16M.
- Trailing 12 Months Year-on-year growth — revenue +7.5%.
- 5-Year Trend Long-term compounding — revenue CAGR 26.9%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 26.93% |
| 1 Year: | 7.50% |
Stock Price Performance
| 1 Year: | -40.89% |
| 6 Months: | +50.11% |
| 3 Months: | -13.64% |
| 1 Month: | -9.52% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMAAbove
- RSI (14)40.26 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 26.9% over 5 years.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
- Trading 45.9% below its 52-week high.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | INM InMed Pharmaceuticals Inc. PHARMA | 1.33 | -0.47 | $7.31M | 0.00% | -57.84% | - | 26.93% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Sep 2019 | Dec 2019 | Mar 2020 | Sep 2020 | Dec 2020 | Mar 2021 | Sep 2021 | Dec 2021 | Mar 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | 276.79K | 437.31K | - | 265.09K | 309.58K | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | 111.56K | 182.28K | -491.02K | 131.16K | 192.51K | 21.24K | 324.14K | 289.46K | 493.41K | 460.89K | 175.62K | 403.16K | 184.19K | - |
| Operating Income | - | - | - | - | -2.24M | -3.10M | -2.97M | -4.28M | -3.48M | -3.51M | -2.10M | -2.00M | -2.54M | - | - | - | - | - | - | - | - |
| Net Income | -2.81M | -2.49M | -2.02M | -1.60M | -2.24M | -3.10M | -2.97M | -4.28M | -3.48M | -3.51M | -2.10M | -2.00M | -2.54M | -1.48M | -1.72M | -1.68M | -2.58M | -2.12M | -1.73M | -2.03M | -2.97M |
| Diluted EPS | - | - | - | - | - | - | -6.17 | -7.73 | -6.14 | -4.06 | -0.91 | -0.60 | -15.24 | -3.71 | -3.58 | -2.71 | -3.64 | -1.94 | -0.44 | -0.51 | -0.73 |
| R&D Expense | 1.96M | 1.61M | 1.27M | 911.16K | 937.95K | 1.77M | 1.49M | 2.54M | 1.75M | 1.38M | 851.36K | 878.30K | 1.29M | 609.79K | 656.76K | 700.14K | 895.18K | 425.37K | 581.61K | 630.64K | 1.02M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Jun 2020 | Jun 2021 | Jun 2022 | Jun 2023 | Jun 2024 | Jun 2025 |
|---|---|---|---|---|---|---|
| Revenue | - | 1.90M | 1.37M | 4.14M | 4.60M | 4.94M |
| Gross Profit | - | - | 543.55K | 1.40M | 1.10M | 1.71M |
| Operating Income | - | -10.20M | -18.60M | -7.95M | - | - |
| Net Income | -8.94M | -10.20M | -18.60M | -7.95M | -7.68M | -8.16M |
| Diluted EPS | - | -37.96 | -33.17 | -3.25 | -20.14 | -8.36 |
| R&D Expense | 5.81M | 5.34M | 7.28M | 3.73M | 3.22M | 2.85M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Jun 2019 | Jun 2020 | Jun 2021 | Jun 2022 | Jun 2023 | Jun 2024 | Jun 2025 |
|---|---|---|---|---|---|---|---|
| Total Assets | - | 7.80M | 9.78M | 12.79M | 14.11M | 11.82M | 15.58M |
| Total Equity | 14.24M | 5.88M | 7.38M | 9.08M | 12.09M | 9.21M | 13.43M |
| Cash & Equivalents | 9.84M | 5.81M | 7.36M | 6.18M | 8.91M | 6.57M | 11.08M |
| Total Liabilities | - | 1.92M | 2.40M | 3.71M | 2.02M | 2.62M | 2.15M |
| Current Liabilities | - | 1.68M | 2.22M | 3.32M | 2.00M | 1.97M | 1.84M |
Cash Flows (Annual)
Figures in USD.
| Metric | Jun 2020 | Jun 2021 | Jun 2022 | Jun 2023 | Jun 2024 | Jun 2025 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -7.37M | -9.79M | -15.58M | -7.28M | -6.99M | -7.77M |
| Investing Cash Flow | 3.79M | -1.73K | -673.00K | -661.80K | -9.29K | - |
| Financing Cash Flow | -30.99K | 10.85M | 15.07M | 10.68M | 4.65M | 12.27M |
| Capital Expenditure | -42.57K | -1.73K | -39.11K | -160.01K | -9.29K | - |
| Free Cash Flow | -7.42M | -9.79M | -15.62M | -7.44M | -7.00M | - |
Ratios (Annual)
Figures in %.
| Metric | Jun 2020 | Jun 2021 | Jun 2022 | Jun 2023 | Jun 2024 | Jun 2025 |
|---|---|---|---|---|---|---|
| Gross Margin % | - | - | 39.8% | 33.9% | 23.9% | 34.5% |
| Operating Margin % | - | -535.9% | -1,361.9% | -192.2% | - | - |
| Net Margin % | - | -535.9% | -1,361.9% | -192.2% | -166.9% | -165.1% |
| ROE % | -152.1% | -138.3% | -204.9% | -65.7% | -83.4% | -60.8% |
| ROCE % | - | -134.9% | -196.5% | -65.7% | - | - |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Adar1 Capital Management, LLC | 14.56% | 800.00K | $1.09M |
| 2 | Vivo Capital, LLC | 14.53% | 798.38K | $1.09M |
| 3 | Squadron Capital Management LLC | 5.92% | 325.00K | $442.00K |
| 4 | Ikarian Capital, LLC | 4.46% | 245.03K | $333.23K |
| 5 | Ursa Fund Management, LLC | 2.29% | 125.80K | $171.09K |
| 6 | Montanova Capital LLC | 1.82% | 100.00K | $136.00K |
| 7 | Boothbay Fund Management, LLC | 1.35% | 74.24K | $100.97K |
| 8 | Sabby Management, LLC | 0.82% | 44.97K | $61.16K |
| 9 | Jane Street Group, LLC | 0.78% | 43.08K | $58.59K |
| 10 | Venrock Adviser, LLC | 0.59% | 32.69K | $44.45K |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for INM
Armistice can buy 278,761 InMed shares at $0.80 after deal - Stock Titan
<a href="https://news.google.com/rss/articles/CBMipwFBVV95cUxNRXRKcVhOeW92VTB5UmJOV2wtc3dQYXFadXlIUHVRbnEzM294Z0t2UGNDNHQtU21KWEZBVUdPazdPWjA2S2s5SXE5eVpOQ3lBYUs1VEVIdkR4a3FLVnY5VmdhelVlWmE0U09STmJyYlA2ejQwdWNLN2VFMEtEX0V3bmd0dW9iaFloRDFiUk…
INM Stock Alert: Halper Sadeh LLC is Investigating Whether InMed Pharmaceuticals, Inc. is Obtaining a Fair Price for its Shareholders - Business Wire
<a href="https://news.google.com/rss/articles/CBMilwJBVV95cUxQWjYyM2pXOWRSa0VrQUFRWDExVmRuRmtiQzFVaXhKSHZ3NFpCUUljWTI5Y0plMVlGSl9ZakluTUE0cW53SUxwQU04ZXo5WXUxNFhJWk9nc21mWGhnX1NOb05zQzZiMy0tVWFLMFlkTGpnQWxmVk9uNE04S3ZNSW1GSFZNYWJGSFdlTktENz…
INM - Finviz
<a href="https://news.google.com/rss/articles/CBMiREFVX3lxTE9ESk12ZWEtdkRad1dVdGpGUlVLWGMwTFl6cFNIQmYtSUNiVl9tTTlpY3JsMHRlQW9PWWxBRktUR0o1MDRx?oc=5" target="_blank">INM</a> <font color="#6f6f6f">Finviz</font>…
INM Stock Alert: What to Know as InMed, Mentari Announce Merger - Barchart.com
<a href="https://news.google.com/rss/articles/CBMiqAFBVV95cUxPdWkwSzNPdHJCQTgwaDEwTUtRazZkazFsQi1wRGVkVm5MLUJieDhnNjJmdnRjWG9wdlp2TC1tR3lSa1VJaThBaTB0aW10VUdVdUpwZ3pOeGFUS19qN2tOeElURUlEanpuZUVDQlNkZFVsemloUHlHYlNVd3RJNTVBTHVmeEQ1UU1NeGN2NT…
INM Stock Jumps As Traders Digest Amended Mentari Merger - StocksToTrade
<a href="https://news.google.com/rss/articles/CBMigwFBVV95cUxNczl1aERyS1hvN1Y0LWNHQi02UmF0VURPaGk5Nl9kNE1vVW5OMTRoRWtoa3gwbnY0Vk0zT0lqalBNT0FKQ21zcGt5eHExTnR5R1duTC1rY1BzeW5mb0lkUUhEd0M4V19Oc0pwRWdRNnZlV05uVHpDaEtzSkUyUmV3bnQ2VQ?oc=5" targe…
InMed-Mentari Migraine Merger Backed by $290 Million Financing Reshapes Company Strategy (INM) - finance.yahoo.com
<a href="https://news.google.com/rss/articles/CBMiqAFBVV95cUxONmFNZzhrb1dkSWVBNjlxckZmLWFHN2hVWEUtMi1zcHNXNEM1Q0FHZEdDTk5fbkNzeGktMW1hYnJoZDZ4NmhjZ2llYmpYTmVhZnVXUGNHRzRYZkxfdEFodWZaU1FrTm9EckNSYTQzSnRSMkU1WVNXZG5HYVVEa1BUdUFhUU9ILVVvVGgxVH…
INM — Frequently Asked Questions
What is the current share price of InMed Pharmaceuticals Inc. (INM)?
As of 2026-09-19 21:16 PDT, InMed Pharmaceuticals Inc. (INM) trades at $1.33 on NasdaqCM. Its 52-week range is $0.62 to $2.46.
What is the market capitalisation of INM?
InMed Pharmaceuticals Inc. (INM) has a market capitalisation of $7.31M on NasdaqCM.
What is the P/E ratio of INM?
INM trades at a trailing price-to-earnings (P/E) ratio of -0.47. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 6.77.
Is INM a good stock to buy?
This page provides a data-driven analysis of InMed Pharmaceuticals Inc. (INM), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.